Thirty three C 19 -diterpenoid alkaloids, twenty-two prepared from known C 19 -diterpenoid alkaloids and eleven isolated from Aconitum and Delphinium spp. were evaluated for their cardiac activity in the isolated bullfrog heart assay. Among them, eleven compounds exhibited cardiac activity, with average rate of amplitude increase in the range of 16-118%. Compound 7, mesaconine (17), hypaconine (25), and beiwutinine (26) exhibited strong cardiac activities relative to the reference drug. The structure-activity relationship data acquired indicated that an -hydroxyl group at C-15, a hydroxyl group at C-8, an -methoxyl or hydroxyl group at C-1, and a secondary amine or N-methyl group in ring A are important structure features necessary for the cardiac activities of the aconitinetype C 19 -diterpenoid alkaloids without any ester groups. In addition, an -hydroxyl group at C-3 is also helpful for the cardiac activity of these alkaloids.
In an earlier study, we reported five cardioactive C 19 -diterpenoid alkaloids that were isolated from the lateral roots of Aconitum carmichaeli Debx. (Ranunculaceae), a distinguished traditional Chinese medicine [1] . The results of this previous study are very helpful to elucidate the mechanism of the cardiac effect of Fu Zi, and also suggest that the C 19 -diterpenoid alkaloids could serve as lead compounds for cardioactive agents. To further investigate the structure-cardiac effect relationships, a series of C 19 -diterpenoid alkaloids were either prepared from naturally occurring alkaloids or were isolated from Aconitum and Delphinium spp. for evaluation of their cardiac effects. The results from the isolated bullfrog heart testing [2] exhibited interesting structure-activity relationships of these C 19 -diterpenoid alkaloids. Herein, we report the preparation and structure-cardiac activity relationships of these alkaloids.
N-Deethylation of C 19 -diterpenoid alkaloids was achieved employing the NBS method developed by us [3, 4] . N-Methylation was accomplished by a classical method, using methyl iodide as a methylating agent. 8-O-Methylation or 8-O-ethylation was conducted according to the procedure reported in the literature [5, 6] . Naturally occurring C 19 -diterpenoid alkaloids, including talatisamine (1), chasmanine (2) , neoline (3), 15-hydroxyneoline (fuziline) (5) , indaconitine (9) , aconine (15), N-dethylaconine (16), mesaconine (17), hypaconine (25), beiwutinine (26), lycoctonine (38), and deltaline (39), were isolated by us from Aconitum or Delphinium spp. (4) , and N-deethyl-15-hydroxyneoline (6) were prepared from neoline (3) and 15-hydroxyneoline (5) , respectively, via the above-mentioned N-deethylation method. Alkaloid 7 was obtained by methylation of compound 6, and alkaloid 8 was prepared from compound 6 according to the method described in the literature [5, 6] . Compound 10 was prepared from indaconitine (9) via N-deethylation, followed by hydrolysis. Compound 11 was prepared by refluxing indaconitine (9) with methanol followed by N-deethylation and hydrolysis. Compound 12 was also prepared from indaconitine (9) by the similar reaction sequence as that described for the preparation of 11, using ethanol instead of methanol as solvent. Compound 13 was prepared from indaconitine (9) through a five-step reaction sequence including Jones oxidation, elimination to remove 1-OCH 3 , hydrogenation, reduction with NaBH 4 , and hydrolysis. Compound 14 was prepared from indaconitine (9) by pyrolysis [7] , dihydroxylation with KMnO 4 -formic acid, N-deethylation, and hydrolysis. Compounds 20 and 22 were prepared from aconitine (18) employing the similar method as that described previously for the synthesis of compounds 11 and 12. N-Methylation of 20 and 22 generated compounds 21 and 23, respectively. Compound 24 was prepared from mesaconitine (19) through a reaction sequence including N-deethylation, N-methylation, Jones oxidation, reduction with NaBH 4 , and hydrolysis. Compound 27 was prepared from aconitine (18) employing the similar method as that described for the preparation of compound 13. Compound 28 was synthesized from compound 27 via a reaction sequence including N-deethylation, N-methylation, and hydrolysis. Compound 29 was prepared from compound 27 using the similar reaction sequence as that described previously for the synthesis of compounds 20 and 28. Compound 30 was synthesized from 27 via a three-step reaction sequence consisting of refluxing with ethanol, N-deethylation, and hydrolysis. Compound 31 was prepared by N-methylation of compound 30. Compounds 32 and 33 were prepared by pyrolysis of aconitine (18), according to the method reported in the literature [8] . Their structures were established by comparison of their 1 H and 13 C NMR data with those reported in the literature [8] , as well as NOESY data. The NOESY spectrum of 33 showed the critical correlation between OCH 3 -16 ( 3.82 s) and H-2", 6" (7.96, d, J = 7.6).
N-Deethylneoline
Reduction of 32 and 33 with NaBH 4 yielded compounds 34 and 35, respectively, via N-deethylation with NBS followed by hydrolysis. Compounds 40 and 41 were prepared from lycoctonine (38) and deltaline (39), respectively, through a three-step reaction sequence including N-deethylation, Pd-C catalytic hydrogenation, and N- (Tables 1, 2) were assigned based on comparison with those of analogs [9, 10] .
Biology: Cardiac effects on the isolated bullfrog hearts of the above-mentioned C 19 -diterpenoid alkaloids ( Table 3) were assayed according to the procedure described in the literature [2] . The cardiac effect was expressed as the average rate of amplitude increase (%). The data were classified into four groups: the average rates of increase in the range of 0-10% (no cardiac effect); the average rates of increase in the range of 12-30% (moderate cardiac effect); the average rates of increase in the range of 31-60% (significant cardiac effect); the average rates of increase were greater than 60% (strong cardiac effect). As illustrated in Table 3 , among the 33 tested C 19 -diterpenoid alkaloids, only compounds 4, 7, 12, 13, 15, 20, 24, and 38, 15-hydroxylneoline (5) , Ndeethylaconine (16), mesaconine (17), hypaconine (25), and beiwutinine (26) are cardioactive. It is worth noting that compound 7, mesaconine (17), hypaconine (25), and beiwutinine (26) did show strong cardiac action relative to the reference drug -strophanthinβ. 15-Hydroxylneoline (5) only exhibited a very short duration of cardiac action.
The structure-activity relationship (SAR) data acquired for the thirty three C 19 -diterpenoid alkaloids showed that they exhibit a broad range (potent-to-inactive) of cardiac effects (the average rates of amplitude increase: -21% to 118%). The structure-activity relationships were summarized as follows:
(1) The C 19 -diterpenoid alkaloids that contain ester groups, such as aconitine, compound 27 etc, did not show any cardiac effect. For the C 19 -diterpenoid alkaloids without any ester groups, if a compound does not contain a hydroxyl group at C-15 {such as talatisamine (1), chasmanine (2), neoline (3), alkaloids 10-13; only compound 4 is an exception here} nor at C-8 (such as 36 and 37), the compound did not show a cardiac effect. On the other hand, an alkaloid with hydroxyl groups at C-15 and C-8, such as aconine (15) and N-deethylaconine (16), did exhibit potent cardiac action. More interestingly, the N-methylated analogs of the above-mentioned group alkaloids, such as mesaconien (17), hypaconine (25), and beiwutinine (26), showed significantly improved cardiac effects relative to their parent compounds. Alkaloids having an N-ethyl group, such as aconine (15) or 15-hydroxylneoline (5), only showed weak or short duration of cardiac action; while its N-deethyl or N-deethyl-N-methyl analog, such as N-deethylaconine (16) or compound 7, exhibited significantly improved cardiac action. These data suggested that 15-OH, 8-OH, and NH (or N-Me) are critical structural features necessary for the cardiac effect of the aconitinetype diterpenoid alkaloids without any esters. In addition, mesaconine (17) and compound 7 are cardioactive, while their analog 28, without 1-OMe or 1-OH, is not cardioactive, indicating that either 1-OCH 3 or 1-OH are also key structural features necessary for the cardiac action.
(2) Replacement of 15-OH in 15-hydroxylneoline (5) and N-deethylaconine (16) with 15-OH (compounds 8 and 14) completely diminished the cardiac action, indicating that the 15-OH is also a determining factor for the cardiac action of C 19 -diterpenoid alkaloids.
(3). The cardiac activity of N-deethylaconine (16) is weaker than that of its N-methyl analog, mesaconine (17), suggesting that the N-methyl group is helpful in improving the cardiac action.
(4) It has been observed that mesaconine (17) has superior protective effects relative to hypaconine (25), including improved inotropic effect and left ventricular diastolic function, on myocardial ischemia-reperfusion injury in rat at a dose of 10 -9 mol/L [1] . Similar results were observed for the cardiac action in the rat heart experiment [11] . These data suggested that the existence of 3-OH is helpful for the cardiac action. However, when the 3-OH in mesaconine (17) was shifted to 3-OH (in compound 24), the cardiac effect was significantly decreased.
(5) Lycotonine-type C 19 -diterpenoid alkaloids, such as lycoctonine (38), deltaline (39), N-deethyl-N-methyllycoctonine (40) and Ndeethyl-N-methyldeltaline (41), did not show any cardiac activity.
In conclusion, the structure-activity relationship data acquired for the thirty three C 19 -diterpenoid alkaloids showed: i) 15-OH, 8-OH, 1-OCH 3 or 1-OH, and NH (or N-Me) are critical structural features necessary for the cardiac effect of the aconitinetype diterpenoid alkaloids without any esters; the existence of 3-OH or NCH 3 
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Preparation of compound 4:
To a solution of neoline (3, 500 mg, 1.14 mmol) in glacial acetic acid (18 mL) was added NBS (600 mg, 3.20 mmol), and the mixture was stirred at room temperature for 3 h prior to being poured into a mixture of ice-water (200 mL). The subsequent mixture was basified with conc. NH 4 OH to pH 10, and extracted with chloroform (50 mL × 3). The combined extracts were rinsed with water (100 mL), dried over anhydrous Na 2 SO 4 , and concentrated to afford a crude product (440 mg), which was purified by CC (silica gel, chloroform: MeOH = 9:1) to yield compound 4 (165 mg, 51%). 
Preparation of compound 7:
To a solution of compound 6 (220 mg, 0.37 mmol) in anhydrous THF was added NaH (9 mg, 0.37 mmol). The mixture was stirred under argon for 15 min before the addition of CH 3 I (24 L, 0.39 mmol). The subsequent mixture was stirred at room temperature for 2 h before the removal of the solvent. The residue was purified by CC over silica gel, eluting with chloroform: 
Preparation of compound 8:
This compound was prepared from neoline (3) according to the procedure described in the literature [12] . Compound 8 was identified by comparison of its 1 H and 13 C NMR data with those reported in the literature [13] .
Preparation of compound 10:
To a solution of indaconitine (9, 100 mg, 0.16 mmol) in glacial acetic acid (5 mL) was added NBS (85 mg, 0.48 mmol), and the mixture was stirred at room temperature for 3 h prior to being basified to pH 10 with conc. NH 4 
Preparation of compound 13:
To a solution of indaconitine (9, 300 mg, 0.48 mmol) in acetone (20 mL) was added, dropwise, Jones reagent (0.6 mL) at 0°C, and the solution was stirred at room temperature for 30 min prior to being quenched with anhydrous Na 2 SO 3 . The subsequent mixture was basified with conc. NH 4 OH to pH 10, and filtered. The solid material was rinsed with acetone, and the solvents were removed under reduced pressure to give residue A (296 mg). The residue A (290 mg) was dissolved in chloroform (10 mL), methanol (10 mL) and conc. NH 4 OH (5 mL), and the mixture was stirred at 50°C for 24 h. Removal of solvent afforded residue B (270 mg). To a solution of residue B (270 mg) in 95% EtOH (15 mL) was added 10% Pd-C (27 mg). The mixture was stirred in the presence of hydrogen at room temperature for 24 h. After filtration, the filtrate was concentrated to give residue C (250 mg). This (240 mg) was reduced with NaBH 4 (45 mg, 1.2 mmol) at room temperature for 3 h to afford the major product (202 mg), which was dissolved in glacial acetic acid (10 mL). To this mixture was added NBS (178 mg, 1.0 mmol), and the reaction mixture was stirred at room temperature for 2 h. The general workup afforded a residue, which was purified by CC over silica gel, eluting with light petroleum: acetone (3:1, 1% diethylamine). The product obtained was treated with a solution of 5% NaOH in methanol (6 mL). The hydrolysis product was purified by CC over silica gel, eluting with chloroform: MeOH (98:2, saturated with conc. NH 4 OH), to afford compound 13 (82 mg, 57%). 1 
Compound 13

Preparation of compound 14:
To a solution of indaconitine (9, 1.9 g, 3.04 mmol) in acetic anhydride (10 mL) was added TsOH (1.0 g), and the mixture was kept stirring at room temperature for 16 h prior to being basified to pH 10 with conc. NH 4 OH at 0°C. The mixture was extracted with chloroform (50 mL × 3). The combining extracts were rinsed with water (50 mL) and dried over anhydrous Na 2 SO 4 , and the chloroform was evaporated to afford residue A (2.36 g).
This was heated at 190-200°C twice, and then purified by CC over silica gel, eluting with cyclohexane: acetone (2:1), to afford the pure pyro-product (1.2 g). To a solution of this (1.2 g) in acetone (45 mL) and H 2 O (5 mL) at 0°C was added KMnO 4 (276 mg, 1.75 mmol), and the mixture was warmed to room temperature and kept stirred at this temperature for 1 h prior to being quenched with Na 2 SO 3 . After filtration, the filtrate was acidified with aq. 10% HCl to pH 3, and then basified with conc. NH 4 OH to pH 10. The mixture was extracted with chloroform to give residue B (1.2 g), which was purified by CC over silica gel, eluting with cyclohexane: acetone (5:1, saturated by conc. NH 4 OH), to afford residue C (0.82 g). Compound 14 (0.31 g, 21%) was prepared from residue C employing the similar procedure as that described for the synthesis of 10. Hz, H-15). 13 
Compound 14
Preparation of compound 21:
To a solution of N-deethyl-8methoxy-14-benzoyl aconine (300 mg, 0.51 mmol), which was obtained during the preparation of 20, in anhydrous THF (15 mL) were added NaH (12 mg, 0.51 mmol) and CH 3 I (35 l), and the mixture was stirred under argon at 0°C for 15 min, and then stirred at room temperature for 2 h. Removal of the solvent afforded a residue, to which was added a solution of 5% NaOH in methanol (15 mL), and the mixture was kept stirring at 60°C for 1 h. A general work-up afforded a crude product, which was purified by CC (silica gel, chloroform: methanol = 95:5, saturated with conc. NH 4 OH) to give compound 21 (160 mg, 52%). Table 1 . HRMS-ESI: m/z[M+H] + calcd for C 25 H 42 NO 9 : 500.2860; found: 500.2852.
Compound 21
Preparation of compound 22:
This compound (95 mg, 35%) was prepared from aconitine (18, 500 mg, 0.77 mmol) using a similar procedure as that used for the synthesis of 12. 
Preparation of compound 23:
To a solution of N-deethyl-8-ethoxy-14-benzoyl aconine (200 mg, 0.33 mmol), obtained during the preparation of compound 22, in anhydrous THF were added NaH (8 mg, 0.33 mmol) and CH 3 I (35 l), and the mixture was stirred at room temperature under argon for 3h. After a general work-up, the crude product was purified by CC over silica gel, eluting with chloroform: methanol (95:5, saturated with conc. NH 4 OH), to give compound 23 (107 mg, 45%). 
Compound 23
Preparation of compound 24:
To a solution of mesaconitine (19, 1 g, 1.5 mmol) in acetone (30 mL) was added Jones reagent (2 mL) at 0°C, and the solution was stirred at room temperature for 30 min prior to being quenched with anhydrous Na 2 SO 3. After filtration, the filtrate was diluted with water, basified with 5% Na 2 CO 3 to pH 9, and extracted with chloroform (30 mL × 3). The combined extracts were dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure to furnish a residue (1 g). Reduction of this with NaBH 4 (480 mL, 12.6 mmol), followed by purification by CC over silica gel, eluting with CHCl 3 : MeOH (98:2), gave 3-epimesaconitine (200 mg, 20%), together with mesaconitine (0.5 g). 3-Epimesaconitine was identified based on comparison of its 1 H ( 13 C) NMR spectroscopic data with those of the authentic sample. 3-Epimesaconitine (200 mg) was dissolved in a solution of 5% NaOH in methanol (8 mL), and the solution was stirred at 60°C for 1 h. A general work-up gave a crude product, which was purified by CC over silica gel, eluting with chloroform: MeOH (95:5) to generate compound 24 (88 mg, 64%). 1 
Compound 24
Preparation of compound 27:
To a solution of aconitine (18, 3.0 g, 4.65 mmol) in acetone (50 mL) was added Jones reagent (1.75 mL, 4.67 mmol) at 0°C, and the solution was stirred at room temperature for 1 h before being quenched with anhydrous Na 2 SO 3 . A general work-up gave a residue, which was purified by CC over silica gel, eluting with light petroleum: acetone (5:1), to give residue C (2.65 g). To a solution of this (2.65 g) in 95% EtOH (80 mL) were added glacial acetic acid (3 mL) and 10% Pd-C (265 mg), and the mixture was stirred in the presence of hydrogen at room temperature for 20 h. Concentration of the reaction solution afforded residue D, which was reduced with NaBH 4 (304 mg, 8.0 mmol) at room temperature for 16 h. A general work-up afford a crude product (2.5 g), which was purified by CC over silica gel, eluting with light petroleum: acetone (5:1), to give compound 27 (1.25 g, 40%). 
Preparation of compound 28:
To a solution of compound 27 (200 mg, 0.33 mmol) in glacial acetic acid (10 mL) was added NBS (175 mg, 0.66 mmol), and the mixture was stirred at room temperature for 4 h. The mixture was basified to pH 10 with conc. NH 4 OH at 0°C and extracted with CHCl 3 (20 mL×3). Removal of solvent gave a residue, which was separated by CC over silica gel, eluting with light petroleum: acetone (2:1, 1% diethylamine) to furnish a residue (125 mg). This was treated with NaH (5.5 mg, 0.21 mmol) and CH 3 I (15 l, 0.24 mmol) under argon at room temperature for 2 h. Removal of the solvent afforded a residue, which was treated with a solution of 5% NaOH in methanol (10 mL) at 60°C for 1 h. A usual work-up gave a crude product, which was purified by CC over silica gel, eluting with chloroform: MeOH (95:5, saturated with conc. NH 4 OH), to afford compound 28 (75 mg, 45%). 1 
Compound 28
Preparation of compound 29:
A solution of compound 27 (305 mg, 0.49 mmol) in methanol (30 mL) was kept refluxing for 20 h. Removal of methanol afforded a residue. Compound 29 (113 mg, 65%) was prepared from this residue using a similar procedure to that described for the preparation of 28. 
Preparation of compound 30:
This compound (82 mg, 31%) was prepared from compound 27 (700 mg, 1.14 mmol) employing a similar method as that described for the preparation of 12.
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Preparation of compound 31:
Compound 31 (101 mg, 37%) was prepared from compound 27 (350 mg, 0.57 mmol) following the procedure described previously for the synthesis of 29. mmol), and the mixture was stirred at 50°C for 2 h. After removal of solvent, the residue was diluted with water, the mixture was basified with conc. NH 4 OH, and the subsequent mixture was extracted with chloroform (50 mL × 3). The combined extracts were dried over anhydrous Na 2 SO 4 and concentrated. The residue obtained was purified by CC over silica gel, eluting with light petroleum: acetone (2:1), to provide a residue (210 mg), which was treated with 10% Pd-C (40 mg) under hydrogen at 60°C for 15 h. A general work-up afforded a residue (200 mg), which was dissolved in THF (10 mL). To this mixture were added NaH (10 mg, 0.416 mmol) and CH 3 I (27 L, 0.437 mmol), and the reaction was allowed to proceed at room temperature for 2 h. Evaporation of solvent, dilution with H 2 O (20 mL), basifying (conc. NH 4 OH), and extraction (CHCl 3 , 10 mL×3) furnished a residue, which was treated with 5% NaOH in methanol (10 mL). A general work-up, followed by CC over silica gel, eluting with chloroform: methanol (95:5, saturated with conc. NH 4 OH), gave compound 40 (72 mg, 44%). 
Compound 40
Preparation of compound 41:
To a solution of deltaline (1.01 g, 2.0 mmol) in isopropanol (40 mL) was added NBS (1.07 g, 6.0 mmol), and the mixture was stirred at 50°C for 2 h. After removal of the solvent, the residue was diluted with water, the mixture basified with conc. NH 4 OH, and extracted with chloroform (50 mL × 3). The combined extracts were dried over anhydrous Na 2 SO 4 and concentrated to give residue A (1 g), which was subjected to CC over silica gel, eluting with light petroleum: acetone (2:1) to furnish residue B (460 mg, 48%). To a solution of residue B (460 mg) in 95% EtOH (23 mL) was added 10% Pd-C (90 mg), and the mixture was stirred under hydrogen at 60°C for 15 h. The insoluble material was filtered off, and the filtrate concentrated to give Ndeethyldeltaline (460 mg). This was identified based on the comparison of its 1 H ( 13 C) NMR spectroscopic data with those of an authentic sample.
To a solution of N-deethyldeltaline (460 mg, 0.96 mmol) in anhydrous THF (15 mL) was added NaH (22 mg, 0.94 mmol), and the mixture was stirred at 0°C for 15 min. Then CH 3 I (63 L, 1.0 mmol) was added, and the reaction allowed to proceed at room temperature for an additional 2 h. Removal of the solvent afforded a residue, which was dissolved in a solution of 5% NaOH in methanol (20 mL). The subsequent mixture was kept stirring at 60°C for 1 h. A general work-up gave a crude product, which was purified by CC over silica gel, using chloroform: methanol (95:5) as eluent, to give compound 41 (310 mg, 74%). 
Compound 41
